• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Massimo Loda, MD


  • Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD.Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.Cancer Res. 2013 Apr 22.
  • Zadra G, Photopoulos C, Loda M.The fat side of prostate cancer.Biochim Biophys Acta. 2013 Apr 2.
  • Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC, Orkin SH, Li Z.ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.Genes Dev. 2013 Mar 15;27(6):683-98.
  • Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X.ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.J Clin Invest. 2013 Mar 1;123(3):1109-22.
  • Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M.Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses.J Cancer Epidemiol. 2013;2013:823849.
  • Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U.Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.J Nucl Med. 2013 Feb;54(2):252-8.
  • Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM.Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.Cancer Discovery. 2013 Jan;3(1):44-51.
  • Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M.EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.Science. 2012 Dec 14;338(6113):1465-9.
  • Kim J, Keay SK, You S, Loda M, Freeman MR.A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2.PLoS ONE. 2012;7(12):e50392.
  • Penney KL, Li H, Mucci LA, Loda M, Sesso HD, Stampfer MJ, Ma J.Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival.Prostate. 2012 Nov 5.
  • Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack EC, Lis R, Kantoff PW, Loda M, Sartor O, Egawa S, Tewari AK, Hahn WC, Freedman ML.Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11252-7.
  • Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon A, Suppan C, Flavin R, Sesso H, Rider JR, Sweeney CS, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci E, Ding EL, Loda M, Mucci LA.The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis.Cancer Epidemiol Biomarkers Prev. 2012 Jun 26.
  • Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH.DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues.PLoS ONE. 2012;7(6):e38881.
  • Nardella C, Lunardi A, Fedele G, Clohessy JG, Alimonti A, Kozma SC, Thomas G, Loda M, Pandolfi PP.Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.Cancer Res. 2011 Mar 28.
  • Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, Mermel CH, Loda M, Ait-Si-Ali S, Garraway LA, Young RA, Zon LI.The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.Nature. 2011 Mar 24;471(7339):513-7.
  • Lee SH, Jia S, Zhu Y, Utermark T, Signoretti S, Loda M, Schaffhausen B, Roberts TM.Transgenic expression of polyoma virus middle T antigen in the mouse prostate gives rise to carcinoma.J Virol. 2011 Mar 16.
  • Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O.RET protein expression in papillary renal cell carcinoma.Urol Oncol. 2011 Mar 9.
  • Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK.Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.Cancer. 2011 Mar 15;117(6):1172-82.
  • Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA.SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.Nature. 2011 Feb 10;470(7333):269-73.
  • Flavin R, Zadra G, Loda M.Metabolic alterations and targeted therapies in prostate cancer.J Pathol. 2011 Jan;223(2):283-94. Review.
  • Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML.Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.PLoS Genet. 2010;6(11):e1001204.
  • Flavin R, Zadra G, Loda M.Metabolic alterations and targeted therapies in prostate cancer.J Pathol. 2010 Oct 14.
  • Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK.Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.Cancer. 2010 Nov 8.
  • Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S.Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.Br J Cancer. 2010 Sep 28;103(7):1025-33.
  • Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA.Genetic variation in RNASEL associated with prostate cancer risk and progression.Carcinogenesis. 2010 Sep;31(9):1597-603.
  • Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M.Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival.J Clin Oncol. 2010 Sep 1;28(25):3958-64.
  • Kenney PA, Wszolek MF, Rieger-Christ KM, Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC.Novel ZEB1 expression in bladder tumorigenesis.BJU Int. 2010 Aug 24.
  • Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B.The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2088-96.
  • Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M.Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis.Am J Pathol. 2010 Jul;177(1):415-23.
  • Zadra G, Priolo C, Patnaik A, Loda M.New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK.Clin Cancer Res. 2010 Jul 1;16(13):3322-8. Review.
  • Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM.A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11002-7.
  • Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE.Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.Br J Cancer. 2010 May 11;102(10):1495-502.
  • Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M.Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors.Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6.
  • Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L.Immunohistochemical expression of BRCA1 and lethal prostate cancer.Cancer Res. 2010 Apr 15;70(8):3136-9.
  • Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP.Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.Sci Signal. 2010;3(117):ra29.
  • Loda M, Kaelin WG.Prostate cancer: beta control your hormones.Cancer Cell. 2010 Apr 13;17(4):311-2.
  • Flavin R, Peluso S, Nguyen PL, Loda M.Fatty acid synthase as a potential therapeutic target in cancer.Future Oncol. 2010 Apr;6(4):551-62. Review.
  • Priolo C, Agostini M, Vena N, Ligon AH, Fiorentino M, Shin E, Farsetti A, Pontecorvi A, Sicinska E, Loda M.Establishment and Genomic Characterization of Mouse Xenografts of Human Primary Prostate Tumors.Am J Pathol. 2010 Apr;176(4):1901-13.
  • Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K.An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.Nat Med. 2010 Mar;16(3):286-94.
  • Barletta JA,Perner S,Iafrate AJ,Yeap BY,Weir BA,Johnson LA,Johnson BE,Meyerson M,Rubin MA,Travis WD,Loda M,Chirieac LR.Clinical Significance of TTF-1 Protein Expression and TTF-1 Gene Amplification in Lung Adenocarcinoma.J Cell Mol Med. 2009 Aug;13(8B):1977-86.
  • Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S.MYC regulation of a "poor-prognosis" metastatic cancer cell state.Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3698-703.
  • Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M.The landscape of somatic copy-number alteration across human cancers.Nature. 2010 Feb 18;463(7283):899-905.
  • Fiorentino M, Capizzi E, Loda M.Blood and tissue biomarkers in prostate cancer: state of the art.Urol Clin North Am. 2010 Feb;37(1):131-41, Table of Contents. Review.
  • Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR.Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.Cancer Res. 2009 Nov 1;69(21):8341-8.
  • Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR.Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.Cancer Res. 2009 Nov 1;69(21):8341-8348.
  • Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG.MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.Cancer Res. 2009 Oct 1;69(19):7803-10.
  • Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, Nosho K, Shima K, Giovannucci EL, Loda M, Fuchs CS.Interaction of molecular markers and physical activity on mortality in patients with colon cancer.Clin Cancer Res. 2009 Sep 15;15(18):5931-6.
  • Wadlow RC, Wittner BS, Finley SA, Bergquist H, Upadhyay R, Finn S, Loda M, Mahmood U, Ramaswamy S.Systems-level modeling of cancer-fibroblast interaction.PLoS ONE. 2009;4(9):e6888.
  • Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP.Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.Sci Signal. 2009;2(84):ra44.
  • Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schöffski P.Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.Semin Oncol. 2009 Aug;36(4):290-301. Review.
  • Snyder EL,Bailey D,Shipitsin M,Polyak K,Loda M.Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies.Lab Invest. 2009 Aug;89(8):857-66.
  • Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M.Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.Cell. 2009 Jul 23;138(2):245-56.
  • Stark JR,Perner S,Stampfer MJ,Sinnott JA,Finn S,Eisenstein AS,Ma J,Fiorentino M,Kurth T,Loda M,Giovannucci EL,Rubin MA,Mucci LA.Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?.J Clin Oncol. 2009 Jul 20;27(21):3459-64.
  • Sabbisetti V, Di Napoli A, Seeley A, Amato AM, O'Regan E, Ghebremichael M, Loda M, Signoretti S.p63 promotes cell survival through fatty acid synthase.PLoS ONE. 2009;4(6):e5877.
  • Snyder EL,Sandstrom DJ,Law K,Fiore C,Sicinska E,Brito J,Bailey D,Fletcher JA,Loda M,Rodig SJ,Dal Cin P,Fletcher CD.c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme.J Pathol. 2009 Jul;218(3):292-300.
  • Nucera C,Eeckhoute J,Finn S,Carroll JS,Ligon AH,Priolo C,Fadda G,Toner M,Sheils O,Attard M,Pontecorvi A,Nose V,Loda M,Brown M.FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3680-9.
  • Nguyen PL,Lin DI,Lei J,Fiorentino M,Mueller E,Weinstein MH,Pagano M,Loda M.The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy.Urol Oncol. 2009 May 16.
  • Yu J,Kane S,Wu J,Benedettini E,Li D,Reeves C,Innocenti G,Wetzel R,Crosby K,Becker A,Ferrante M,Cheung WC,Hong X,Chirieac LR,Sholl LM,Haack H,Smith BL,Polakiewicz RD,Tan Y,Gu TL,Loda M,Zhou X,Comb MJ.Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.Clin Cancer Res. 2009 May 1;15(9):3023-8.
  • Nanni S,Benvenuti V,Grasselli A,Priolo C,Aiello A,Mattiussi S,Colussi C,Lirangi V,Illi B,D'Eletto M,Cianciulli AM,Gallucci M,De Carli P,Sentinelli S,Mottolese M,Carlini P,Strigari L,Finn S,Mueller E,Arcangeli G,Gaetano C,Capogrossi MC,Donnorso RP,Bacchetti S,Sacchi A,Pontecorvi A,Loda M,Farsetti A.Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.J Clin Invest. 2009 May;119(5):1093-108.
  • Priolo C,Oh WK,Loda M.Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.IDrugs. 2009 Mar;12(3):165-8. Review.
  • Migita T,Ruiz S,Fornari A,Fiorentino M,Priolo C,Zadra G,Inazuka F,Grisanzio C,Palescandolo E,Shin E,Fiore C,Xie W,Kung AL,Febbo PG,Subramanian A,Mucci L,Ma J,Signoretti S,Stampfer M,Hahn WC,Finn S,Loda M.Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.Journal of the National Cancer Institute. 2009 Apr 1;101(7):519-32.
  • Bertagnolli MM,Warren RS,Niedzwiecki D,Mueller E,Compton CC,Redston M,Hall M,Hahn HP,Jewell SD,Mayer RJ,Goldberg RM,Saltz LB,Loda M.p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.Clin Cancer Res. 2009 Mar 15;15(6):2116-22.
  • Nardella C,Carracedo A,Alimonti A,Hobbs RM,Clohessy JG,Chen Z,Egia A,Fornari A,Fiorentino M,Loda M,Kozma SC,Thomas G,Cordon-Cardo C,Pandolfi PP.Differential requirement of mTOR in postmitotic tissues and tumorigenesis.Sci Signal. 2009;2(55):ra2.
  • Du J,Bernasconi P,Clauser KR,Mani DR,Finn SP,Beroukhim R,Burns M,Julian B,Peng XP,Hieronymus H,Maglathlin RL,Lewis TA,Liau LM,Nghiemphu P,Mellinghoff IK,Louis DN,Loda M,Carr SA,Kung AL,Golub TR.Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.Nat Biotechnol. 2009 Jan;27(1):77-83.
  • Jeong JH,Wang Z,Guimaraes AS,Ouyang X,Figueiredo JL,Ding Z,Jiang S,Guney I,Kang GH,Shin E,Hahn WC,Loda MF,Abate-Shen C,Weissleder R,Chin L.BRAF activation initiates but does not maintain invasive prostate adenocarcinoma.PLoS ONE. 2008;3(12):e3949.
  • Mandeville JA,Silva Neto B,Vanni AJ,Smith GL,Rieger-Christ KM,Zeheb R,Loda M,Libertino JA,Summerhayes IC.P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells.BJU Int. 2008 Dec;102(11):1707-14.
  • Ogino S,Nosho K,Meyerhardt JA,Kirkner GJ,Chan AT,Kawasaki T,Giovannucci EL,Loda M,Fuchs CS.Cohort study of fatty acid synthase expression and patient survival in colon cancer.J Clin Oncol. 2008 Dec 10;26(35):5713-20.
  • Fiorentino M,Zadra G,Palescandolo E,Fedele G,Bailey D,Fiore C,Nguyen PL,Migita T,Zamponi R,Di Vizio D,Priolo C,Sharma C,Xie W,Hemler ME,Mucci L,Giovannucci E,Finn S,Loda M.Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.Lab Invest. 2008 Dec;88(12):1340-8.
  • Ogino S,Nosho K,Kirkner GJ,Kawasaki T,Meyerhardt JA,Loda M,Giovannucci EL,Fuchs CS.CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.Gut. 2009 Jan;58(1):90-6.
  • Firestein R,Bass AJ,Kim SY,Dunn IF,Silver SJ,Guney I,Freed E,Ligon AH,Vena N,Ogino S,Chheda MG,Tamayo P,Finn S,Shrestha Y,Boehm JS,Jain S,Bojarski E,Mermel C,Barretina J,Chan JA,Baselga J,Tabernero J,Root DE,Fuchs CS,Loda M,Shivdasani RA,Meyerson M,Hahn WC.CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.Nature. 2008 Sep 25;455(7212):547-51.
  • Ince TA,Ward JM,Valli VE,Sgroi D,Nikitin AY,Loda M,Griffey SM,Crum CP,Crawford JM,Bronson RT,Cardiff RD.Do-it-yourself (DIY) pathology.Nat Biotechnol. 2008 Sep;26(9):978-9; discussion 979.
  • Carvalho MA,Zecchin KG,Seguin F,Bastos DC,Agostini M,Rangel AL,Veiga SS,Raposo HF,Oliveira HC,Loda M,Coletta RD,Graner E.Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model.Int J Cancer. 2008 Dec 1;123(11):2557-65.
  • Saad AG,Yeap BY,Thunnissen FB,Pinkus GS,Pinkus JL,Loda M,Sugarbaker DJ,Johnson BE,Chirieac LR.Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.Cancer. 2008 Oct 15;113(8):2129-38.
  • Majumder PK,Grisanzio C,O'Connell F,Barry M,Brito JM,Xu Q,Guney I,Berger R,Herman P,Bikoff R,Fedele G,Baek WK,Wang S,Ellwood-Yen K,Wu H,Sawyers CL,Signoretti S,Hahn WC,Loda M,Sellers WR.A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.Cancer Cell. 2008 Aug 12;14(2):146-55.
  • Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ.Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.Nature.;454:776-9.
  • Di Vizio D,Adam RM,Kim J,Kim R,Sotgia F,Williams T,Demichelis F,Solomon KR,Loda M,Rubin MA,Lisanti MP,Freeman MR.Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase.Cell Cycle. 2008 Jul 15;7(14):2257-67.
  • Jia S,Liu Z,Zhang S,Liu P,Zhang L,Lee SH,Zhang J,Signoretti S,Loda M,Roberts TM,Zhao JJ.Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.Nature. 2008 Aug 7;454(7205):776-9.
  • Mosquera JM,Perner S,Genega EM,Sanda M,Hofer MD,Mertz KD,Paris PL,Simko J,Bismar TA,Ayala G,Shah RB,Loda M,Rubin MA.Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.Clin Cancer Res. 2008 Jun 1;14(11):3380-5.
  • Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ.Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients.Mod Pathol. 2008 Jun;21(6):676-84.
  • Laios A, Toole SO, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barret C, Loda M, Gleeson N, Arcy TD, McGuinness EP, Sheils O, Sheppard B, Leary JO.Potential role of miR-9 and miR-223 in recurrent ovarian cancer.Mol Cancer. 2008 Apr 28;7(1):35.
  • Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE.Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor.Hum Pathol. 2008 Mar;39(3):410-9.
  • Febbo PG, Mulligan MG, Slonina DA, Stegmeir K, Di Vizio D, Martinez PR, Loda M, Taylor SC.Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis.BMC Genomics. 2007;8:461.
  • Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, Ogino S.WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer.Mod Pathol. 2008 Feb;21(2):150-8.
  • Hittelman A, Sridharan S, Roy R, Fridlyand J, Loda M, Collins C, Paris PL.Evaluation of whole genome amplification protocols for array and oligonucleotide CGH.Diagn Mol Pathol. 2007 Dec;16(4):198-206.
  • Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, Sellers WR.Identification of prostate cancer modifier pathways using parental strain expression mapping.Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17771-6.
  • Silva Neto B, Smith GL, Mandeville JA, Vanni AJ, Wotkowicz C, Rieger-Christ KM, Baumgart E, Jacobs MA, Cohen MS, Zeheb R, Loda M, Libertino JA, Summerhayes IC.Prognostic significance of altered p120 ctn expression in bladder cancer.BJU Int. 2008 Mar;101(6):746-52.
  • Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR, Lisanti MP.Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression.Cancer Biol Ther. 2007 Aug;6(8):1263-8.
  • Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM.DNA degradation test predicts success in whole-genome amplification from diverse clinical samples.J Mol Diagn. 2007 Sep;9(4):441-51.
  • Nieto M, Finn S, Loda M, Hahn WC.Prostate cancer: Re-focusing on androgen receptor signaling.Int J Biochem Cell Biol. 2007;39(9):1562-8. Review.
  • Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS.Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.J Mol Diagn. 2007 Jul;9(3):305-14.
  • Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL.Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.Cancer Cell. 2007 Jun;11(6):555-69.
  • Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS.Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.Hum Pathol. 2007 Jun;38(6):842-9.
  • Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS.Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample.J Mol Diagn. 2007 May 3.
  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery .Corrigendum: High-throughput oncogene mutation profiling in human cancer.Nat Genet. 2007 Apr;39(4):567.
  • Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS.CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.Virchows Arch. 2007 May;450(5):529-537.
  • Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS.Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype.Hum Pathol. 2007 Apr;38(4):585-92.
  • Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS.TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.Hum Pathol. 2007 Apr;38(4):614-20.
  • Signoretti S, Loda M.Prostate stem cells: From development to cancer.Semin Cancer Biol. 2007 Jun;17(3):219-24. Review.
  • Baumgart E, Cohen MS, Neto BS, Jacobs MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M, Libertino JA, Summerhayes IC.Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.Clin Cancer Res. 2007 Mar 15;13(6):1685-94.
  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA.High-throughput oncogene mutation profiling in human cancer.Nat Genet. 2007 Mar;39(3):347-351.
  • Byers RJ, Di Vizio D, O'connell F, Tholouli E, Levenson RM, Gossard K, Twomey D, Yang Y, Benedettini E, Rose J, Ligon KL, Finn SP, Golub TR, Loda M.Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution.J Mol Diagn. 2007 Feb;9(1):20-9.
  • Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS.Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP.Mod Pathol. 2007 Jan;20(1):15-22.
  • Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS.CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.J Mol Diagn. 2006 Nov;8(5):582-8.
  • De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS.A working group classification of focal prostate atrophy lesions.Am J Surg Pathol. 2006 Oct;30(10):1281-91.
  • Ogino S, Kawasaki T, Kirkner G, Ogawa A, Dorfman I, Loda M, Fuchs C.Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.J Pathol. 2006 Oct;210(2):147-54.
  • Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M.The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis.Cancer Res. 2006 Sep 1;66(17):8625-32.
  • Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS.Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.Am J Surg Pathol. 2006 Sep;30(9):1175-83.
  • Tholouli E, Hoyland JA, Di Vizio D, O'Connell F, Macdermott SA, Twomey D, Levenson R, Yin JA, Golub TR, Loda M, Byers R.Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies.Biochem Biophys Res Commun. 2006 Sep 22;348(2):628-36.
  • Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI.The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function.Cancer Res. 2006 Aug 1;66(15):7668-77.
  • Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J.Development of an integrated prostate cancer research information system.Clin Genitourin Cancer. 2006 Jun;5(1):61-6.
  • Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS.Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis.Mod Pathol. 2006 Aug;19(8):1083-90.
  • Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS.Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.Neoplasia. 2006 Jun;8(6):458-64.
  • Rossi S, Ou W, Tang D, Bhattacharya N, Dei Tos A, Fletcher J, Loda M.Gastrointestinal stromal tumours overexpress fatty acid synthase.J Pathol. 2006 Jul;209(3):369-75.
  • Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M.Androgen-dependent regulation of Her-2/neu in prostate cancer cells.Cancer Res. 2006 Jun 1;66(11):5723-8.
  • Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A.Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.Mol Cancer Res. 2006 Feb;4(2):79-92.
  • Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub T, George D.Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.Clin Cancer Res. 2006 Jan 1;12(1):152-8.
  • Signoretti S, Loda M.Defining cell lineages in the prostate epithelium.Cell Cycle. 2006 Jan;5(2):138-41.
  • Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM.The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18443-8.
  • Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M.p63 regulates commitment to the prostate cell lineage.Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11355-60.
  • Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC.Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10238-43.
  • Lechpammer M, Xu X, Ellis FH, Bhattacharaya N, Shapiro GI, Loda M.Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.Oncogene. 2005 Mar 3;24(10):1683-8.
  • Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC.Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.Cancer Res. 2004 Dec 15;64(24):8867-75.
  • Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR.mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.Nat Med. 2004 Jun;10(6):594-601.
  • Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M.The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer.Cancer Cell. 2004 Mar;5(3):253-61.
  • Baron A, Migita T, Tang D, Loda M.Fatty acid synthase: a metabolic oncogene in prostate cancer?.J Cell Biochem. 2004 Jan 1;91(1):47-53.
  • Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR.Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP.Cancer Res. 2003 Aug 15;63(16):4781-5.
  • Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M.Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.Mol Cancer Res. 2003 Aug;1(10):707-15.
  • Sellers WR, Loda M.The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?.Cancer Cell. 2002 Nov;2(5):349-50.
  • Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M.Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.J Clin Invest. 2002 Sep;110(5):633-41.
  • Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR.Gene expression correlates of clinical prostate cancer behavior.Cancer Cell. 2002 Mar;1(2):203-9.
  • DeSalle LM, Latres E, Lin D, Graner E, Montagnoli A, Baker RT, Pagano M, Loda M.The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein.Oncogene. 2001 Sep 6;20(39):5538-42.
  • Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M.Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27.Mol Endocrinol. 2001 May;15(5):765-82.
  • Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M.Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.Nat Med. 1997 Feb;3(2):231-4.